ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER

描述（由申请人提供）：我们建议建立一个综合的白血病转化科学中心（LTSC），该中心将在ECOG-ACRIN和国家临床试验网络（NCTN）内产生、协调和领导白血病转化研究。LTSC将作为白血病实验室委员会（LLC）研究的中心枢纽，得到白血病转化实验室（LTRL）、白血病组织库（LTB）和一个全面的白血病数据仓库的支持。LTSC由E. Paietta、A. Melnick和R. Levine领导，他们共同领导有限责任公司、ltl和LTB。通过这些举措，他们在白血病生物学的转化研究领导和最先进的相关研究的实施方面发展了广泛的跟踪记录。通过与纽约基因组中心的合作，LTSC进一步得到加强，该中心提供高通量基因组技术，最先进的基因组平台，计算资源以及执行广泛的clia认证的临床基因组分析的能力。为了最大限度地加快基于最重要科学的高质量临床试验，LTSC将建立一个互动框架，吸引初级和高级临床研究人员、实验室科学家、计算生物学家、生物统计学家等，并使他们能够形成协同研究团队。LTSC将为跨学科团队提供试点项目资金，以启动这些项目，并提供广泛的科学资源，包括患者标本、LTRL、访问纽约基因组中心、基因组和表观遗传分析数据库以及科学支持。通过这种方式，LTSC将确保转化科学研究无缝集成到白血病临床试验中，以确定反应/结果的预测因素，确定和测试新疗法，并开发创新的相关研究来评估抗白血病疗法的反应。通过这些活动，LTSC希望通过个性化诊断方法、生物标志物和治疗方法的开发和实施来改变白血病治疗的标准实践。

DESCRIPTION (provided by applicant): We propose to create an integrated Leukemia Translational Science Center (LTSC), which will generate, coordinate and lead translational studies in leukemia within ECOG-ACRIN and within the National Clinical Trials Network (NCTN). The LTSC will serve as the central hub for studies of the Leukemia Laboratory Committee (LLC), with the support of the Leukemia Translational Laboratory (LTRL), the Leukemia Tissue Bank (LTB), and a comprehensive Leukemia Data Warehouse. The LTSC is led by E. Paietta, A. Melnick and R. Levine, who collectively lead the LLC, LTRL and LTB. Through these initiatives, they have developed an extensive track record in translational research leadership and implementation of state-of-the-art correlative studies in leukemia biology. The LTSC is further enhanced through its partnership with the New York Genome Center, which provides access to high-throughput genomics technologies, state-of-the-art genomic platforms, computational resources, and the capability to perform extensive, CLIA-certified, clinical genomics assays. In order to maximally accelerate high quality clinical trials based on the most important science, the LTSC will establish an interaction framework that will attract junior and senior clinical investigators, laboratory scientists, computational biologists, biostatisticians and others, and enable them to form synergistic research teams. The LTSC will provide pilot project funding for cross-disciplinary teams to jump-start these projects and an extensive suite of scientific resources, including patient specimens, the LTRL, access to the New York Genome Center, genomic and epigenetic profiling databases, and scientific support. In this way, the LTSC will ensure that translational scientific studies are seamlessly integrated into leukemia clinical trials to identify predictors of response/outcome, identify and test novel therapies, and develop innovative correlative studies to assess response to anti-leukemia therapies. Through these activities, the LTSC expects to transform the standard practice of leukemia care with the development and implementation of personalized diagnostic methods, biomarkers and therapies.